- CROMSOURCE, an international full service contract research organization (CRO), today ...
Grade Recommendation: Strong (Highest) GREENWICH, Connecticut, Feb. 11, 2013 ...
- Joseph F. Finn, Jr., C.P.A. ("Finn") Assignee for the Benefit of Creditors of Epix Pharmaceuticals, ...
- - Findings from Two-Year Pivotal Phase III TEMSO Trial ...
- March 2011 Data Confirm Strong Treatment Effect of ...
- - elure Advanced Skin Lightening Products captures the ...
- - Polyplus-transfection celebrates 10 years of commercial growth and research and ...
- Call for Nations to ...
-FDA allows use of investigational new drug for life-threatening indications Edison ...
Gadjah Mada University (UGM) will hold a national seminar on the benefits, safety and development prospects of ...
- - First Presentations of European-Australian and North American Phase III Trials ...
- - The Additional Funds Will Enable the Company to Expand its Therapeutic ...
- Broadens later stage capabilities and Increases Asian ...
-VerifyNow System to be used in Drug Developer's Clinical Studies Accumetrics, Inc., a privately-held ...
Gene mutations which cause a rare kidney disease may also be involved in obsessive compulsive disorder (OCD), ...